Your browser is no longer supported. Please, upgrade your browser.
Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-2.53 Insider Own0.10% Shs Outstand122.75M Perf Week-3.96%
Market Cap4.43B Forward P/E- EPS next Y-1.96 Insider Trans-49.08% Shs Float122.23M Perf Month-1.98%
Income-305.60M PEG- EPS next Q-0.62 Inst Own- Short Float5.33% Perf Quarter24.65%
Sales63.00M P/S70.34 EPS this Y-43.30% Inst Trans-0.03% Short Ratio4.58 Perf Half Y11.28%
Book/sh3.40 P/B10.62 EPS next Y23.10% ROA-57.20% Target Price49.11 Perf Year52.51%
Cash/sh3.40 P/C10.62 EPS next 5Y33.10% ROE-62.10% 52W Range20.68 - 41.20 Perf YTD25.17%
Dividend- P/FCF- EPS past 5Y-40.00% ROI-52.90% 52W High-12.38% Beta3.76
Dividend %- Quick Ratio10.70 Sales past 5Y53.00% Gross Margin88.80% 52W Low74.56% ATR1.21
Employees420 Current Ratio10.80 Sales Q/Q31317.50% Oper. Margin- RSI (14)48.01 Volatility3.24% 3.27%
OptionableYes Debt/Eq0.00 EPS Q/Q12.30% Profit Margin- Rel Volume0.75 Prev Close35.40
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.42M Price36.10
Recom2.00 SMA20-3.61% SMA502.97% SMA20010.27% Volume1,068,924 Change1.98%
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
Apr-16-15Initiated Leerink Partners Outperform $48
Mar-12-15Reiterated Needham Buy $40 → $38
Feb-24-15Initiated H.C. Wainwright Buy $50
Feb-06-15Resumed ROTH Capital Buy $42
Dec-22-14Reiterated Needham Buy $26 → $40
Aug-07-13Reiterated Needham Buy $16 → $26
Aug-07-13Reiterated Ladenburg Thalmann Buy $15 → $24
Oct-16-17 08:07AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-13-17 03:01PM  Valeant Reports Positive Results on Psoriasis Drug Siliq Zacks
09:02AM  Lilly's Verzenio Gets Priority Review in First-Line Setting Zacks
08:07AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-12-17 06:56PM  Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017 Zacks
08:16AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-11-17 03:34PM  Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA Zacks
11:09AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : October 11, 2017 Capital Cube
Oct-10-17 04:50PM  Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel Zacks
09:34AM  Why Should You Invest in Novo Nordisk (NVO) Stock Right Now Zacks
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-09-17 09:25AM  Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit Zacks
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-06-17 08:40AM  Pros And Cons Of All The News Out Of Acadia Pharma This Week Benzinga
08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-05-17 04:47PM  This Biotech Rockets Then Dips After FDA Breakthrough Win Investor's Business Daily
02:20PM  Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response Benzinga
11:57AM  ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status Zacks
10:52AM  Ligand (LGND) Signs Deal to Acquire Crystal Bioscience Zacks
10:07AM  Acadia Pharma Could Rise Another 25 Percent to $50 Investopedia
09:01AM  Acadia Pharma Stock Rockets On Drug Breakthrough Nod Investor's Business Daily
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and ImmunoGen ACCESSWIRE
Oct-04-17 06:49PM  Acadia shares rise on FDA dementia drug designation MarketWatch
06:43PM  2 Stocks Move in After-Hours Trading GuruFocus.com
04:05PM  ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis Business Wire
Sep-26-17 05:07PM  Allergan Authorizes New $2B Share Buyback Plan, Stock Up Zacks
11:13AM  Biotech Acadia Could Rise 30 Percent To $50 Investopedia
Sep-25-17 08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-22-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-21-17 03:00PM  Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You? Motley Fool
Sep-19-17 03:12PM  Supernus Drops SPN-810's Lower Dose Test in Phase III Trials Zacks
09:00AM  ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017 Business Wire
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-18-17 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-15-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-14-17 05:50PM  GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down Zacks
11:05AM  Alexion (ALXN) Reports Interim Results for Soliris Study Zacks
Sep-13-17 11:29AM  Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick Zacks
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks
08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-11-17 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
Sep-08-17 05:06PM  Nuplazid for Long-Term Care: Revenue Driver for Acadia? Market Realist
03:36PM  Nuplazid Sees Increasing Physician Intent to Prescribe in 2017 Market Realist
02:01PM  Nuplazid Expected to Become a Leading Central Nervous System Drug Market Realist
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
11:55AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : September 7, 2017 Capital Cube
10:32AM  Merck (MRK) Opts for Buying German Immuno-Oncology Biotech Zacks
09:08AM  Acadia Could Report Robust Revenue Growth in 2017 Market Realist
07:37AM  What Analysts Recommend for Acadia Pharmaceuticals in September Market Realist
Sep-05-17 11:47AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Capital Cube
Aug-30-17 11:06AM  FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down Zacks
03:00AM  Stocks To Watch: Acadia Pharmaceuticals Sees RS Rating Jump To 83 Investor's Business Daily
Aug-29-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-28-17 07:02PM  Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval Zacks
Aug-27-17 01:37PM  3 Stocks That Turned $8,000 Into at Least $138,000 in 5 Years Motley Fool
Aug-25-17 10:45AM  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars Zacks
10:23AM  Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate Zacks
Aug-24-17 02:34PM  Kite Pharma at New 52-Week High: What's Driving the Stock? Zacks
Aug-23-17 04:06PM  Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data Zacks
Aug-22-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-21-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-18-17 10:28AM  Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer Zacks
Aug-17-17 10:22AM  FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa Zacks
08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-14-17 02:30PM  Edited Transcript of ACAD earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
10:37AM  Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern Zacks
Aug-12-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-11-17 08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-10-17 08:20AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE -8.97%
08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-09-17 03:33PM  'Longing' for Acadia Pharmaceuticals? Here's How to Play It TheStreet.com +12.42%
01:43PM  Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today Motley Fool
12:24PM  Acadia Shares Up Big On Strong Sales, Increased Confidence Benzinga
10:25AM  Why Acadia Pharma Is One of Wednesdays Best Earnings Reports 24/7 Wall St.
08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
06:00AM  Biotech Acadia Sends a Loud Message to the Market Investopedia
Aug-08-17 11:54PM  Acadia reports 2Q loss Associated Press
04:09PM  Acadia reports 2Q loss Associated Press
04:05PM  ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results Business Wire
01:00PM  Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 10:32AM  Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More Zacks
Aug-02-17 08:49AM  Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season? Zacks
Aug-01-17 04:07PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : August 1, 2017 Capital Cube
09:00AM  ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017 Business Wire
Jul-25-17 09:00AM  ACADIA Pharmaceuticals Named to Forbes Magazines List of Worlds Most Innovative Growth Companies Business Wire
Jul-21-17 01:44PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 21, 2017 Capital Cube
01:15PM  7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods TheStreet.com
Jul-18-17 08:16AM  These 2 Companies Have No Competition Motley Fool
Jul-13-17 08:20AM  Today's Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Mylan N.V. Accesswire
Jul-12-17 03:07PM  ACADIA Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACAD) : July 12, 2017 Capital Cube
Jul-11-17 09:19AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : July 11, 2017 Capital Cube
Jul-10-17 01:49PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 10, 2017 Capital Cube -5.45%
Jun-27-17 02:47PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 27, 2017 Capital Cube
08:54AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : June 27, 2017 Capital Cube
Jun-23-17 08:04AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jun-19-17 02:33PM  3 Value Stocks You Haven't Thought Of Motley Fool
Jun-16-17 03:19PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
Jun-05-17 01:58PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:59AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorOct 13Option Exercise1.381,426,5901,968,69423,763,865Oct 16 05:15 PM
Baity GlennEVP AND GCOct 05Option Exercise1.9128,50054,330107,156Oct 06 06:20 PM
Baity GlennEVP AND GCOct 05Sale40.9137,5001,534,04369,656Oct 06 06:20 PM
Baity GlennEVP AND GCOct 04Option Exercise1.8511,00020,34078,656Oct 06 06:20 PM
Baity GlennEVP AND GCAug 30Option Exercise1.6216,50726,74194,163Sep 01 05:15 PM
Baity GlennEVP AND GCAug 30Sale34.8726,507924,31567,656Sep 01 05:15 PM
Baity GlennEVP AND GCAug 09Option Exercise1.6214,32223,13791,978Aug 11 05:38 PM
Baity GlennEVP AND GCAug 09Sale34.8814,322499,53477,656Aug 11 05:38 PM
Baity GlennEVP AND GCAug 04Option Exercise1.626,50010,53077,656Aug 08 06:29 PM
Baity GlennEVP AND GCJul 20Option Exercise1.6228,09745,517109,253Jul 21 05:25 PM
Baity GlennEVP AND GCJul 20Sale30.0038,0971,142,91071,156Jul 21 05:25 PM
Baity GlennEVP AND GCJun 22Option Exercise1.621,9033,08383,059Jun 26 05:35 PM
Baity GlennEVP AND GCJun 22Sale30.001,90357,09181,156Jun 26 05:35 PM
Baity GlennEVP AND GCMay 15Option Exercise1.6214,09322,83181,156May 17 05:42 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Option Exercise34.457,856270,6399,527Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Sale39.657,856311,4901,671Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Option Exercise28.4466,7521,898,34868,423Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Sale39.8866,7522,662,1161,671Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Option Exercise19.611,70033,3373,371Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Sale39.651,70067,4051,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Option Exercise6.7126,365176,83993,428Feb 16 07:05 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Option Exercise19.6187,1281,708,58090,759Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Sale39.6989,0883,535,5731,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Sale39.6626,3651,045,51767,063Feb 16 07:05 PM
Baity GlennEVP AND GCFeb 01Option Exercise1.5521,07832,67198,141Feb 03 06:50 PM
Baity GlennEVP AND GCFeb 01Sale35.1531,0781,092,38267,063Feb 03 06:50 PM
Baity GlennEVP AND GCDec 28Option Exercise1.625,5008,91077,063Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Option Exercise1.559,80015,19081,363Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Sale30.469,800298,47471,563Dec 29 05:09 PM
Baity GlennEVP AND GCDec 20Option Exercise1.5510,00015,50081,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 20Sale30.0010,000300,00171,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 19Option Exercise1.648,63514,16171,563Dec 21 07:03 PM
Baity GlennEVP AND GCNov 10Option Exercise1.5510,20015,81073,121Nov 14 07:00 PM
Baity GlennEVP AND GCNov 10Sale30.0710,200306,68762,921Nov 14 07:00 PM